Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | RPS6KB2 | Q9UBS0 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9310588 | 0.94 | NPC1 (0.45) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL9438481 | 0.90 | ADORA2A (0.54) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL3088300 | 0.88 | NPC1 (0.46) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL19148655 | 0.84 | KDM4E (0.58) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL11021110 | 0.83 | ADORA2A (0.51) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL11702923 | 0.83 | ADORA2A (0.51) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL30104195 | 0.81 | KDM4E (0.56) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL28960097 | 0.81 | KDM4E (0.56) | KDM4EMAPTL3MBTL1MEN1HPGD | |
| SCHEMBL1560087 | 0.81 | KDM4E (0.53) | KDM4EMEN1KMT2AALDH1A1ADORA2A | |
| SCHEMBL5017654 | 0.80 | CYP19A1 (0.44) | KDM4EMAPTL3MBTL1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0096657-A2 | 2-Phenyl-2-naphthyl and 2-heterocyclic pyrimidines as antidotes for protecting cultured plants before phytotoxic damages caused by herbicides | CIBA-GEIGY AG (CH) | 1983-12-21 | — | — | EP | claimed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| EP-1697351-A1 | 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058883-A1 | 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-5304647-A | Addition of an organolithium reagent; dehydrogenation of addition product; two-phase conditions prevents hydrolysis | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1994-04-19 | — | — | US | disclosed |
| US-4963676-A | INTERMEDIATES FOR NOVEL UNFUSED HETEROBICYCLIC COMPOUNDS WITH BIOLOGICAL ACTIVITY; ANTICANCER AGENTS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4929726-A | ANTICARCINOGENIC AGENTS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1990-05-29 | — | — | US | disclosed |
| WO-1989007599-A2 | NOVEL DIAZINES AND THEIR METHOD OF PREPARATION | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-08-24 | — | — | WO | disclosed |
| EP-0096657-B1 | 2-PHENYL-2-NAPHTHYL AND 2-HETEROCYCLIC PYRIMIDINES AS ANTIDOTES FOR PROTECTING CULTURED PLANTS BEFORE PHYTOTOXIC DAMAGES CAUSED BY HERBICIDES | CIBA-GEIGY AG (CH) | 1989-04-05 | — | — | EP | disclosed |
| US-4698091-A | 2-phenylpyrimidines, 2-naphthylpyrimidines and 2-heterocyclylpyrimidines as safeners for protecting cultivated plant against phytotoxic damage caused by herbicides | CIBA-GEIGY CORPORATION (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0096657-A2 | 2-Phenyl-2-naphthyl and 2-heterocyclic pyrimidines as antidotes for protecting cultured plants before phytotoxic damages caused by herbicides | CIBA-GEIGY AG (CH) | 1983-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | KDM4E 3504/4885MAPT 1877/4885L3MBTL1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.